Precision medicine and personalized reimbursement: The next frontier for payers & providers

Precision medicine has transformed healthcare from organ-based treatment algorithms to biologically stratified care. Genomic sequencing, pharmacogenomics, biomarker-driven oncology, and advanced gene and cell therapies now allow physicians to tailor interventions to each patient’s molecular profile. In many cases, this approach delivers not just incremental improvement but durable remission or functional cure.

Despite these advances, current reimbursement systems remain rooted in fee-for-service (FFS), a model designed to reward repeatable procedures and standardized encounters. This creates a growing gap between how value is generated in modern medicine and how it is reimbursed. Achieving sustainable deployment of precision medicine at scale requires structural modernization of reimbursement, operational excellence in billing, and coordinated collaboration among payers, providers, and life sciences stakeholders.

Why traditional reimbursement models fall short, paying for activity rather than outcomes

Fee-for-service reimbursement prioritizes the number of services delivered: office visits, infusions, procedures, and diagnostic tests. This model worked in an era when treatment pathways were generally uniform, but it misaligns with the principles of precision medicine. For example, a biomarker-selected therapy administered once may outperform months of empirical chemotherapy, and a single gene therapy infusion can replace decades of conventional treatment.

Under fee-for-service, providers earn more revenue from multiple infusions than from a single, biologically precise intervention. Consequently, the unit of payment often does not reflect the true unit of clinical value.

Coding systems lag molecular science

Billing infrastructure still depends on CPT and ICD codes, which were designed around procedures and diagnoses rather than genomic subtypes. Patients coded identically for the same disease may have completely different molecular drivers, yet reimbursement treats them the same.

Companion diagnostics are critical to precision care, but payer coverage remains inconsistent. Rapidly evolving molecular pathology codes, combined with preauthorization requirements, often force providers to submit extensive documentation linking mutation status to therapy selection. Denials typically result from coding or documentation gaps rather than inappropriate clinical care. This is a structural limitation, not a clerical issue.

Coverage variability and administrative friction

Coverage policies differ widely across commercial insurers, Medicare contractors, and Medicaid programs. Most payers require:

• Preauthorization before molecular testing.
• Documentation of guideline adherence.
• Mutation confirmation before drug approval.
• Evidence of prior therapy failure.

These requirements create delays even when patients clearly meet eligibility criteria, which is critical in metastatic cancers where progression can occur in weeks. The reimbursement system was originally designed for population-level therapeutics and has not been adapted for mutation-driven urgency.

Short-term budget focus vs long-term value

Financial misalignment is especially pronounced in commercial insurance, where member turnover often occurs within two to three years. Payer’s funding high-cost curative therapies rarely retain patients long enough to realize downstream cost savings from avoided hospitalizations or chronic care.

Gene therapies exemplify this tension: multimillion-dollar upfront costs are often evaluated within annual budget cycles, even when long-term models demonstrate net cost offsets relative to lifelong treatment. Hospital payment structures compound the challenge: DRG bundles aggregate patients under a single reimbursement category, masking molecular distinctions and averaging value across diverse treatment pathways.

Structural contrast: Volume-based vs personalized reimbursement

The gap between legacy fee-for-service and emerging personalized reimbursement models can be described across several core dimensions.

In fee-for-service, payment is triggered by the number of services delivered, patient classification relies on CPT/ICD codes, financial exposure is short-term, and outcome risk is primarily borne by the payer. Claims data alone suffice, but the model is poorly suited to high-cost, one-time interventions such as gene or cell therapies.

By contrast, personalized reimbursement links payment to clinical outcomes or episode-level value. Patients are classified using biomarker-informed frameworks, financial exposure is often frontloaded or distributed over multiple years, and outcome risk is shared between payer and manufacturer, sometimes including the provider. Implementation requires integrated claims, EHR, and registry-based real-world evidence, making it naturally adaptable to high-cost, individualized interventions.

Personalized reimbursement: A structural shift

Aligning payment with precision medicine requires structural reform rather than minor coding updates. Personalized reimbursement includes a portfolio of models designed to reward therapeutic durability and measurable outcomes.

Outcomes-based contracts

Outcomes-based contracts tie reimbursement to predefined clinical endpoints, such as remission, survival milestones, or functional improvement. If outcomes fall short, financial adjustments are applied through rebates or refunds. Effective implementation depends on selecting endpoints that are clinically meaningful, measurable in routine practice, and appropriate for timely adjudication.

Installment payment models

Installment frameworks distribute high-cost therapy payments over multiple years, contingent on sustained clinical benefit. This approach reduces liquidity shocks, smooths actuarial risk, and aligns cash flow with therapeutic durability - particularly relevant for gene and cell therapies.

Indication-specific pricing

Some oncology drugs are approved for multiple indications with variable survival benefits. Indication-specific pricing aligns reimbursement with evidence-based value, requiring systems that link claims to the documented clinical context, ensuring payment reflects actual clinical benefit rather than a generalized average.

Coverage with evidence development (CED)

CED allows conditional reimbursement while real-world data are collected. Participation in registries or structured reporting may be required. This strategy balances early patient access with ongoing evidence generation, particularly in small, biomarker-defined populations where conventional trials may be impractical.

Real-world evidence integration

RWE derived from EHRs, claims databases, and genomic registries provides longitudinal insight across diverse populations. Structured integration supports adjudication under value-based contracts and enables iterative policy refinement. Success depends on interoperable systems and standardized governance.

Operational excellence in billing

High-performing precision medicine programs emphasize:

• Rigorous documentation linking biomarker findings to therapy decisions.
• Continuous education on molecular pathology coding updates
• Proactive preauthorization and coverage verification
• Denial monitoring and root-cause analysis
• Cross-functional collaboration among clinicians, coders, laboratory teams, and revenue cycle leadership

Technology supports accuracy, but sustainable success depends on discipline, oversight, and continuous workflow refinement.

Payer–provider collaboration imperative

Personalized reimbursement cannot succeed through unilateral reform. It requires aligned infrastructure and shared governance.

Shared data architecture

Value-based payment depends on longitudinal patient tracking. Claims data alone are insufficient; biomarker status, treatment response, and outcomes must be captured in EHRs and registries. Interoperability standards and governance frameworks addressing privacy, consent, and auditability are essential.

Joint clinical pathways & risk stabilization

Co-developed pathways reduce denial rates and administrative friction. Embedding biomarker-confirmed therapies into preapproved pathways transforms reimbursement from adversarial review to aligned accountability. For small, biomarker-defined cohorts, risk pooling, reinsurance, and multiyear reassessment clauses stabilize exposure while preserving outcome alignment.

Aligning economics with molecular medicine

Precision medicine has redefined clinical possibility, yet reimbursement systems remain partly rooted in procedural repetition and population homogeneity. Predictable consequences include coding complexity, prior authorization delays, and short-term budget resistance.

Sustainable implementation requires progress along three strategic dimensions:

• Structural Modernization of Payment Models, aligning reimbursement with durable outcomes rather than service volume.
• Operational Discipline in Billing and Documentation, ensuring accuracy in coding, preauthorization, and claims management.
• Institutional Collaboration Across Stakeholders, fostering shared governance and aligned incentives among payers, providers, and life sciences partners.

With these measures, precision medicine can progress from scientific aspiration to clinical standard, ensuring reimbursement systems enable innovation instead of obstructing it.

Author: Ratna Gupta, Practice Lead – Healthcare and Life Sciences, Tata Elxsi